Monitor for dilution impact on SPRC shareholders via NeuroThera's share issuance; assess whether CliniQ’s quantum platform can deliver tangible R&D acceleration for SciSparc’s CNS drug programs. Watch for patent filings and fundraising activity that could trigger earn-outs.
Price Chart
Executive Summary
SciSparc Ltd. (SPRC) announced that its majority-owned subsidiary, NeuroThera Labs, is acquiring 54.01% of quantum technology firm CliniQuantum Ltd. in a stock-and-earnout deal valued at approximately $9.46 million, plus potential earn-outs of up to $2.5 million. The transaction reflects a strategic expansion into quantum computing for clinical trial optimization, though it is being funded entirely through equity issuance by a subsidiary, raising dilution concerns.
Key Financial Metrics
Key Facts
- NeuroThera Labs (75%-owned by SciSparc) is acquiring 54.01% of CliniQuantum Ltd. via a share purchase agreement.
- Consideration is 56,600,000 NeuroThera shares, valued at ~$9,459,954 based on 20-day VWAP on TSXV.
- Potential earn-out payments of up to $2.5 million: $1.5M tied to patent filings, $1M to NeuroThera fundraising proceeds.
- Closing expected by March 31, 2026, subject to Israeli tax ruling and closing conditions.
- CliniQ holds quantum simulation patents from Tel Aviv University and aims to use quantum computing to improve clinical trial design.
Financial Impact
$9.46 million initial value with up to $2.5 million in contingent payments
Risk Factors
- High dilution risk: 56.6M shares issued by NeuroThera may significantly dilute SciSparc's indirect stake.
- CliniQ is pre-revenue with unproven quantum technology; commercial viability is uncertain.
- Earn-out structure benefits sellers but adds contingent liability and potential future dilution if paid in stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252980 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers